SRZN
NASDAQSurrozen Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$21.75+0.46 (+2.19%)
02:15 PM02:45 PM
News · 26 weeks59-89%
2025-12-142026-06-07
Mix3290d
- Insider13(41%)
- SEC Filings10(31%)
- Other6(19%)
- Offering2(6%)
- Analyst1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Kutzkey Tim4 - Surrozen, Inc./DE (0001824893) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Surrozen Inc.SCHEDULE 13D/A - Surrozen, Inc./DE (0001824893) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.SCHEDULE 13G/A - Surrozen, Inc./DE (0001824893) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.SCHEDULE 13G/A - Surrozen, Inc./DE (0001824893) (Subject)
- INSIDERSEC Form 4 filed by Director Rothenberg Mace4 - Surrozen, Inc./DE (0001824893) (Issuer)
- INSIDERSEC Form 4 filed by Director Woodhouse David J4 - Surrozen, Inc./DE (0001824893) (Issuer)
- INSIDERSEC Form 4 filed by Director Haak-Frendscho Mary4 - Surrozen, Inc./DE (0001824893) (Issuer)
- INSIDERSEC Form 4 filed by Director Chai Christopher Y4 - Surrozen, Inc./DE (0001824893) (Issuer)
- INSIDERSEC Form 4 filed by Director Bjerkholt Eric4 - Surrozen, Inc./DE (0001824893) (Issuer)
- INSIDERSEC Form 4 filed by Director Berkenblit Anna4 - Surrozen, Inc./DE (0001824893) (Issuer)
- SECSurrozen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Surrozen, Inc./DE (0001824893) (Filer)
- PRSurrozen to Present at Upcoming Healthcare Investor ConferenceSOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference. H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 Fireside Chat at 11:30 AM Eastern Time / 8:30 AM Pacific Time Interested parties may access the live audio webcast for the conference via the Investors section of the Surrozen website at https://investors.s
- SECSEC Form 10-Q filed by Surrozen Inc.10-Q - Surrozen, Inc./DE (0001824893) (Filer)
- SECSurrozen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Surrozen, Inc./DE (0001824893) (Filer)
- PRSurrozen Reports First Quarter 2026 Financial Results and Provides Business UpdateOn track to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Well-capitalized with $106.9 million in cash and cash equivalents as of March 31, 2026 SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced financial results for the first quarter ended March 31, 2026 and provided a business update. Business Highlights Surrozen remains focused on advancing a new generation of ophthal
- INSIDERExec. Vice President, Research Li Yang converted options into 4,375 shares and sold $52,799 worth of shares (1,584 units at $33.33), increasing direct ownership by 19% to 17,216 units (SEC Form 4) to satisfy withholding obligation4 - Surrozen, Inc./DE (0001824893) (Issuer)
- INSIDERChief Operating Officer Williams Charles O converted options into 5,625 shares and sold $67,866 worth of shares (2,036 units at $33.33), increasing direct ownership by 28% to 16,571 units (SEC Form 4) to cover taxes4 - Surrozen, Inc./DE (0001824893) (Issuer)
- INSIDERChief Executive Officer Parker Craig C sold $150,798 worth of shares (4,524 units at $33.33) and converted options into 12,500 shares, increasing direct ownership by 93% to 16,553 units (SEC Form 4) to satisfy tax liability4 - Surrozen, Inc./DE (0001824893) (Issuer)
- PRSurrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that on April 24, 2026, Surrozen granted a non-statutory stock option for an aggregate of 2,020 shares of Surrozen common stock to a recently hired non-executive employee as an inducement material to their acceptance of employment with Surrozen. The stock option was granted under Surrozen's 2025 Equity Inducement Plan which provides for the grant of equity awards to new
- SECSEC Form SCHEDULE 13G filed by Surrozen Inc.SCHEDULE 13G - Surrozen, Inc./DE (0001824893) (Subject)
- ANALYSTTD Cowen initiated coverage on SurrozenTD Cowen initiated coverage of Surrozen with a rating of Buy
- INSIDERSEC Form 4 filed by Li Yang4 - Surrozen, Inc./DE (0001824893) (Issuer)
- SECSEC Form DEFA14A filed by Surrozen Inc.DEFA14A - Surrozen, Inc./DE (0001824893) (Filer)
- SECSEC Form DEF 14A filed by Surrozen Inc.DEF 14A - Surrozen, Inc./DE (0001824893) (Filer)
- SECSEC Form EFFECT filed by Surrozen Inc.EFFECT - Surrozen, Inc./DE (0001824893) (Filer)
SRZN FAQ
6 questionsWhat does Surrozen Inc. do?
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific...Where does SRZN stock trade?
Surrozen Inc. (SRZN) is listed on NASDAQ.What sector and industry is SRZN in?
Surrozen Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about SRZN?
Surrozen Inc. has had 7 recent analyst actions on file. The most recent action was from TD Cowen: Buy on 2026-04-21. Recent price targets range from $1100.00 to $4500.00.What companies are similar to SRZN?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare SRZN side-by-side with any of them on Quantisnow.How can I track SRZN on Quantisnow?
Quantisnow aggregates Surrozen Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SRZN to receive live email and push alerts on every new disclosure.